Non-invasive early detection of Fetal Growth Restriction (FGR), many cases are never detected under the current standard of care.
Reduces total cost to healthcare providers while improving accuracy and reducing uncertainties.
Based on research
Our research efforts were initiated in an anechoic chamber which allowed us to isolate the sounds recorded from pregnant women. World-class danish acoustic expertise and experience has been the foundation for Centaflow since the early years.
→
We have made thousands of recordings of sounds emitted through the skin of the human abdomen and we now know how to diagnose FGR based on our passive listening technology which does not input any energy into the body of the subject being assessed.
Sound patterns from blood flows can be used to characterise malformation of the placenta.
Detection of the biomarker is highly correlated with present or future fetal growth restriction.
Centaflow detects the biomarker and has been proven to provide accurate prediction of FGR.
Our close collaboration with healthcare professionals has allowed us to perfect the device and its use, and we are receiving consistently positive feedback.
The device has been developed through several iterations that have all contributed significantly to the final design.
Safety and usability have been our main concerns every time we have improved the design.
We work closely with universities and leverage the latest development in the field of Artificial Intelligence.
This allows us to derive precise and pertinent health-related information from the signals we gather from the human body.